Effects of food intake on the pharmacokinetics of diclofenac potassium soft gelatin capsules: A single-dose, randomized, two-way crossover study

Clinical Therapeutics

Volumn 31, Issue 10, 2009, Pages 2233-2241

  Scallion, Ralph ^a   Moore, Keith A ^b  

^a AAI Human Pharmacology Center   (United States)

^b Xanodyne Pharmaceuticals Inc   (United States)

Author keywords

absorption; bioequivalence; diclofenac potassium; dispersion technology; pharmacokinetics; ProSorb

Indexed keywords

DICLOFENAC POTASSIUM; GELATIN; PHENYLEPHRINE; PROSORB; UNCLASSIFIED DRUG; ZIPSOR;

ADULT; AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG ELIMINATION; DRUG TOLERABILITY; FEMALE; FOOD INTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; NOSE CONGESTION; RANDOMIZED CONTROLLED TRIAL; SEX RATIO; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; CAPSULES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DICLOFENAC; FEMALE; FOOD-DRUG INTERACTIONS; GELATIN; HUMANS; INTESTINAL ABSORPTION; MALE; YOUNG ADULT;

EID: 71649107081     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.10.001     Document Type: Article

References (32)

1. Mitchell J.A., Akarasereenont P., Thiemermann C., et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A 90 (1993) 11693-11697
2. Moore N. Diclofenac potassium 12.5mg tablets for mild to moderate pain and fever: A review of its pharmacology, clinical efficacy and safety. Clin Drug Investig 27 (2007) 163-195
3. Bakshi R., Frenkel G., Dietlein G., et al. A placebocontrolled comparative evaluation of diclofenac dispersible versus ibuprofen in postoperative pain after third molar surgery. J Clin Pharmacol 34 (1994) 225-230
4. Breivik E.K., Barkvoll P., and Skovlund E. Combining diclofenac with acetaminophen or acetaminophen-codeine after oral surgery: A randomized, double-blind single-dose study. Clin Pharmacol Ther. 66 (1999) 625-635
5. Hersh E.V., Levin L.M., Adamson D., et al. Dose-ranging analgesic study of Prosorb diclofenac potassium in postsurgical dental pain. Clin Ther. 26 (2004) 1215-1227
6. Matthews R.W., Scully C.M., and Levers B.G. The efficacy of diclofenac sodium (Voltarol) with and without paracetamol in the control of post-surgical dental pain. Br Dent J. 157 (1984) 357-359
7. Bamber M.J., Tweedie I.E., Breeze C., and Williams N.E. Premedication with controlled release diclofenac sodium reduces post-operative pain after minor gynaecological surgery. Eur J Anaesthesiol 14 (1997) 421-427
8. McEvoy A., Livingstone J.I., and Cahill C.J. Comparison of diclofenac sodium and morphine sulphate for postoperative analgesia after day case inguinal hernia surgery. Ann R Coll Surg Engl. 78 (1996) 363-366
9. Drug Topics. Top 200 generic drugs by units in 2006. http://www.drugtopics.com/drugtopics/data/articlestandard//drugtopics/09 2007/407652/article.pdf Accessed February 12, 2008
10. US Food and Drug Administration (FDA). Label and approval history for Voltaren. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseacti on=Search.Overview&DrugName=VOLTAREN Accessed February 13, 2008
11. Graham D.J., Campen D., Hui R., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective nonsteroidal anti-inflammatory drugs: Nested case-control study. Lancet 365 (2005) 475-481
12. Hippisley-Cox J., and Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: Population based nested case-control analysis. BMJ 330 (2005) 1366
13. Mitchell J.A., and Warner T.D. Cyclo-oxygenase-2: Pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol 128 (1999) 1121-1132
14. Cataflam (diclofenac) [package insert] (2001), Novartis Pharmaceuticals, Inc, East Hanover, NJ
15. Mojaverian P., Rocci Jr. M.L., Conner D.P., et al. Effect of food on the absorption of enteric-coated aspirin: Correlation with gastric residence time. Clin Pharmacol Ther. 41 (1987) 11-17
16. Sánchez J., MartÍnez L., Garcia-Barbal J., et al. The influence of gastric emptying on droxicam pharmaco-kinetics. J Clin Pharmacol 29 (1989) 739-745
17. Welling P.G. Interactions affecting drug absorption. Clin Pharmacokinet 9 (1984) 404-434
18. Vidon N., Pfeiffer A., Godbillon J., et al. Evaluation of the gastric absorption and emptying of drugs under various pH conditions using a simple intubation method: Application to diclofenac. Br J Clin Pharmacol 28 (1989) 121-124
19. Riad L.E., Sawchuk R.J., McAlary M.M., and Chan K.K. Effect of food on the multiple-peak behavior after a single oral dose of diclofenac sodium slow-release tablet in humans. Am J Ther. 2 (1995) 237-242
20. Terhaag B., Gramatte T., Hrdlcka P., et al. The influence of food on the absorption of diclofenac as a pure substance. Int J Clin Pharmacol Ther Toxicol 29 (1991) 418-421
21. Willis J.V., Kendall M.J., and Jack D.B. The influence of food on the absorption of diclofenac after single and multiple oral doses. Eur J Clin Pharmacol 19 (1981) 33-37
22. Laska E.M., Sunshine A., Marrero I., et al. The correlation between blood levels of ibuprofen and clinical analgesic response. Clin Pharmacol Ther. 40 (1986) 1-7
23. Seymour R.A., Hawkesford J.E., Weldon M., and Brewster D. An evaluation of different ibuprofen preparations in the control of postoperative pain after third molar surgery. Br J Clin Pharmacol 31 (1991) 83-87
24. Metropolitan Life Insurance Ideal Weights for Height, 1983 (1980), Recording and Statistical Corporation, Philadelphia, Pa [source: 1979 Build Study, Society of Actuaries and Association of Life Insurance Medical Directors of America]
25. Dept of Health and Human Services, US Food and Drug Administration. Code of Federal Regulations, Title 21, Parts 50, 56, and 312. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?C FRPart=312&showFR=1&subpartNode=21:5.0.1.1.3.2 Accessed September 1, 2009
26. ICH Expert Working Group. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6(R1). http://www.ich.org/LOB/media/MEDIA482.pdf Accessed September 1, 2009
27. US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Food-Effect Bioavailability and Fed Bioequivalence Studies (2002). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati on/Guidances/ucm070241.pdf Accessed October 5, 2009
28. Mead R. The Design of Experiments: Statistical Principles for Practical Applications (1988), Cambridge University Press, New York, NY
29. US Food and Drug Administration. Food and drug interactions. The Benefits and Risks of Pain Relievers Q & A on NSAIDs. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm107856.htm Accessed September 1, 2009
30. Ceppi Monti N., Gazzaniga A., Gianesello V., et al. Activity and pharmacokinetics of a new oral dosage form of soluble ibuprofen. Arzneimittelforschung 42 (1992) 556-559
31. Chan A.T., Manson J.E., Albert C.M., et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 113 (2006) 1578-1587
32. Laine L. Gastrointestinal effects of NSAIDs and coxibs. J Pain Symptom Manage 25 Suppl 2 (2003) S32-S40